Introduction
============

Glioblastoma is the most common and fatal malignant primary brain tumor in adults, with an incidence rate of 2.8 cases per 100,000 individuals per year and a perioperative mortality rate of 2.2% ([@b1-ol-0-0-4526]). It is estimated that 44,500 new cases of primary brain tumors were diagnosed in the USA in 2005, of which glioblastoma accounted for \~20% ([@b2-ol-0-0-4526]). The traditional treatment method is surgical resection combined with fractionated radiotherapy and adjuvant chemotherapy with temozolomide ([@b3-ol-0-0-4526]). However, despite advances in surgical techniques, postoperative supportive care, radiation and adjuvant systemic chemotherapy, the 5-year survival rate of glioblastoma remains at \<10% ([@b4-ol-0-0-4526]). The disease generally recurs at the resection margin, and the median survival time is \~14 months; extremely few patients have a long-term survival, which highlights the importance of understanding the peripheral brain tumor region ([@b5-ol-0-0-4526]).

Glioblastoma cells are capable of infiltrating deep into the surrounding tissue, which allows these cells to migrate for long distances. This is typical behavior of neural stem cells, from which glioblastoma cells originate ([@b6-ol-0-0-4526]). Previous studies have demonstrated that malignant tumors may be affected by stromal cells, and that cancer cells may be controlled by the microenvironment; it has been reported that the non-neoplastic, stromal compartment of the majority of solid cancers is involved in tumor invasion, proliferation and metastasis ([@b7-ol-0-0-4526]--[@b9-ol-0-0-4526]).

In glioblastoma, a novel population of stromal cells that surround the tumor, termed glioblastoma-associated stromal cells (GASCs), has been isolated and analyzed. These cells have a different molecular expression profile compared with that of control stromal cells derived from non-glioblastoma peripheral brain tissues ([@b7-ol-0-0-4526]). GASCs have been revealed to have a phenotype and functional properties similar to that of cancer-associated fibroblasts located in the stroma of carcinomas, which are known to be important in the growth and progression of tumors ([@b10-ol-0-0-4526]). However, the genetic information concerning this novel cell population is relatively scarce.

The aim of the present study was to analyze the transcriptome and differentially expressed genes (DEGs) in GASCs. Bioinformatics analysis was performed using the microarray GSE24100, which is based on samples of GASCs and control stromal cells. In addition, functional and pathway enrichment analysis was performed and a protein-protein interaction (PPI) network was constructed. A sub-network was also constructed for additional analysis.

Materials and methods
=====================

### Microarray data

Microarray data was obtained from the study by Clavreul *et al* ([@b7-ol-0-0-4526]), which is referenced in the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)) under accession number GSE24100. The microarray GSE24100 was detailed using Whole Human Genome Microarray 4×44K (catalog no., G4112F; design ID, 014850; Agilent Technologies, Santa Clara, CA, USA), and the data contains a total of 7 samples, consisting of 3 control stromal cell samples and 4 GASC samples.

### Data preprocessing and DEG analysis

Using the limma model ([@b11-ol-0-0-4526]) on R/Bioconductor software version 2.15.1 ([www.bioconductor.org/](www.bioconductor.org/)) and the microarray probe annotation profile from Brain Array Lab ([brainarray.mbni.med.umich.edu/Brainarray/](brainarray.mbni.med.umich.edu/Brainarray/)), the probe-level data was converted into expression measures, during which background correction, quantile normalization and probe summarization were performed. A t-test ([@b12-ol-0-0-4526]) was used to identify the significantly expressed DEGs in GASC samples, with a combination of P\<0.05 and the \|log~2~FC (fold change)\| \>1 used as the threshold. A heat map was generated using Z-score normalization of log~2~ expression values to illustrate the relative expression levels of DEGs in GASCs.

### Gene ontology (GO) and pathway enrichment analysis of DEGs

GO is a commonly used approach for functional studies, and three independent ontologies (biological process, molecular function and cellular component) are accessible on the world-wide web ([www.geneontology.org](www.geneontology.org)) ([@b13-ol-0-0-4526]). Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.jp/kegg/](www.genome.jp/kegg/)) is a knowledge base for the systematic analysis of gene functions, which links genomic information with higher order functional information ([@b14-ol-0-0-4526]). In the present study, GO biological processes and KEGG pathway analysis were performed using the Database for Annotation, Visualization and Integrated Discovery; (<http://david.abcc.ncifcrf.gov/home.jsp>) ([@b15-ol-0-0-4526]) where P\<0.05.

### Functional annotation of DEGs

Functional annotation of DEGs was performed for the detection of transcription factors and tumor-associated genes. Two databases, Tumor Suppressor Gene Database version 2.0 ([@b16-ol-0-0-4526]) ([bioinfo.mc.vanderbilt.edu/TSGene/](bioinfo.mc.vanderbilt.edu/TSGene/))and Tumor Associated Gene database (last modified, 10/03/2014) ([@b17-ol-0-0-4526]) ([www.binfo.ncku.edu.tw/TAG/GeneDoc.php](www.binfo.ncku.edu.tw/TAG/GeneDoc.php)) were used to screen tumor suppressor genes and oncogenes.

### PPI network construction

The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; [string-db.org/](string-db.org/)) database is a pre-computed global resource for the investigation and analysis of associations between proteins. The database reveals protein interactions, including experimental and predicted protein interaction information ([@b18-ol-0-0-4526]). In the present study, STRING was used to analyze the interactions between DEGs with the PPI required confidence (combined score, 0.9) and a PPI network was constructed. In addition, the degree of the nodes in the PPI network were calculated, and the nodes with a higher degree were deemed to be hub proteins compared with the other nodes in the PPI network.

### Selection and pathway enrichment analysis of sub-network

To obtain additional information on the genes identified in the PPI network, a sub-network was constructed using CFinder ([www.cfinder.org/](www.cfinder.org/)) and Clique Percolation Method (k=3) ([@b19-ol-0-0-4526]). Four networks were obtained, but only one was associated with additional nodes and was additionally analyzed. GO and KEGG enrichment analysis were performed on the sub-network for the majority of nodes, and the interactions were selected using CFinder version 2.0.5 for the identification of significant pathways.

Results
=======

### DEG selection

In total, 512 transcripts were observed to be expressed differentially, including 337 upregulated transcripts and 175 downregulated transcripts, corresponding to 331 upregulated genes and 171 downregulated genes. The heat map of DEGs in GASCs and control stromal cells is shown in [Fig. 1](#f1-ol-0-0-4526){ref-type="fig"}.

### GO categories and KEGG pathway enrichment analysis of DEGs

Pathways obtained by KEGG enrichment are presented in [Table I](#tI-ol-0-0-4526){ref-type="table"}. According to the results, upregulated genes were primarily enriched in pathways associated with the cell cycle, DNA replication, oocyte meiosis and p53 signaling ([Table IA](#tI-ol-0-0-4526){ref-type="table"}). Downregulated genes were primarily enriched in pathways associated with adipocytokine signaling, aldosterone-regulated sodium reabsorption and nucleotide oligomerization domain-like receptor signaling ([Table IB](#tI-ol-0-0-4526){ref-type="table"}).

Several GO categories were enriched among DEGs and are shown in [Table I](#tI-ol-0-0-4526){ref-type="table"}. The upregulated genes were primarily enriched in categories associated with mitotic sister chromatid segregation, cell cycle checkpoint and DNA metabolic processes, which are all associated with cell mitosis and DNA replication ([Table IC](#tI-ol-0-0-4526){ref-type="table"}). Among downregulated genes, categories with increased transcripts included regulation of blood pressure and cellular response to mechanical stimulus ([Table ID](#tI-ol-0-0-4526){ref-type="table"}).

### Functional annotation of DEGs

According to the annotation results ([Table II](#tII-ol-0-0-4526){ref-type="table"}), 11 transcriptional factors were upregulated, including breast cancer 1, early onset (*BRCA1*) and BRCA1 interacting protein C-terminal helicase 1, and 6 transcriptional factors were downregulated, including ary-hydrocarbon receptor nuclear translocator 2 and DNA damage inducible transcript 3 (*DDIT3*).

Additionally, among the upregulated genes, 9 oncogenes were identified \[including cyclin A2 (*CCNA2*) and cyclin D2 (*CCND2*)\] in addition to 23 tumor suppressor genes (including kinase anchoring protein 12 and BRCA1-associated RING domain 1). The downregulated genes included 3 oncogenes (such as Rho guanine nucleotide exchange factor 5 and *DDIT3)* and 10 tumor suppressor genes (such as cadherin 4, type 1, R-cadherin and ATPase, aminophospholipid transporter, class I, type 8A, member 2). The details are presented in [Table II](#tII-ol-0-0-4526){ref-type="table"}.

### PPI network construction

The PPI network constructed for the DEGs is shown in [Fig. 2](#f2-ol-0-0-4526){ref-type="fig"}, in which 181 nodes and 1,740 interactions were identified. In this network, 8 nodes with higher degrees were identified, including cyclin-dependent kinase 1 (*CDK1*), *CCNA2*, mitotic checkpoint serine/threonine kinase (*BUB1*), cell division cycle 20 (*CDC20*), kinetochore complex component 80 (*NDC80*), non-SMC condensing I complex, subunit G (NCAPG), cell division cycle associated-8 and polo-like kinase 1 (*PLK1*).

### Analysis of sub-network

The sub-network obtained using CFinder is shown in [Fig. 3](#f3-ol-0-0-4526){ref-type="fig"}, in which 135 nodes and 1,694 interactions were identified, and all nodes were upregulated genes. KEGG enrichment in the sub-network is presented in [Table IIIA](#tIII-ol-0-0-4526){ref-type="table"}; cell cycle, p53 signaling pathway, oocyte meiosis and progesterone-mediated oocyte maturation were the predominant pathways enriched by these DEGs. GO enrichment analysis was also performed and is presented in [Table IIIB](#tIII-ol-0-0-4526){ref-type="table"}; mitotic cell cycle, DNA metabolic process and nuclear division were the predominant categories.

Discussion
==========

Glioblastoma is the most aggressive cerebral tumor in humans, and has a high annual mortality rate ([@b20-ol-0-0-4526]). GASCs represent a novel stromal cell population that express mesenchymal markers and exert tumor-promoting effects ([@b7-ol-0-0-4526]). In the present study, 3 samples of GASCs and 4 of control stromal cells were used to identify DEGs, and the functional categories associated with those DEGs, that are altered between GASCs and control stromal cells in glioblastoma. In total, 502 DEGs were identified, including 331 upregulated genes and 171 downregulated genes, including *CDK1*, *BUB1*, *CDC20*, *CCNA2*, *NDC80*, *NCAPG* and *PLK1*. These are hub genes and serve major roles in pathways of the cell cycle, p53 signaling, oocyte meiosis and progesterone-mediated oocyte maturation as determined from the results of KEGG pathway enrichment analysis. In addition, the upregulated gene BRCA1 was identified to be a transcription factor. The predominant pathway in which the majority of hub genes were enriched was the cell cycle, which is expected as glioblastoma cell invasion requires that cells have enhanced motility and the ability to degrade local tissue barriers ([@b21-ol-0-0-4526]).

CDK1 protein belongs to the CDK family, which controls the cell cycle by catalyzing the transfer of phosphate from ATP to specific protein substrates. CDKs have been established as master regulators of cell proliferation ([@b22-ol-0-0-4526]). As expected, in the present study, *CDK1* was upregulated in GASCs and was primarily enriched in pathways involved in the cell cycle, mitotic cell cycle and DNA replication, all of which are closely associated with the mechanisms of tumor growth ([@b23-ol-0-0-4526],[@b24-ol-0-0-4526]). In the cell cycle, CDK1 controls a widespread regulatory system, which involves phosphorylation of other regulatory molecules and phosphorylation of the molecular machinery that drives the cell-cycle ([@b25-ol-0-0-4526]). Furthermore, in the current study, CDK1 was observed to be enriched in the p53 signaling pathway, which is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 signaling network is an integral tumor suppressor pathway in glioblastoma pathogenesis that affects cellular processes, including cell cycle control and cell death execution ([@b26-ol-0-0-4526]). In this pathway, the tumor suppressor p53 protein acts as a transcriptional activator of p53-regulated genes ([@b27-ol-0-0-4526]) and is primarily involved in control of numerous genes governing cell survival, cell proliferation, angiogenesis and metabolism ([@b28-ol-0-0-4526]). Stegh *et al* ([@b26-ol-0-0-4526]) reported that the p53 signaling pathway is inhibited in glioblastoma, which causes aberrant cell cycling and tumorigenesis. In the present study, several DEGs were enriched in the p53 signaling pathway, including *CDK1*, *CDK2*, *CCNB1* and *CCND2*, which may be associated with the inhibition of p53 signaling ([@b29-ol-0-0-4526]). Therefore, according to the current study, upregulated *CDK1* may increase the growth of glioblastoma by promoting cell cycle pathways and inhibiting the p53 signaling pathway.

*BUB1* was identified to be upregulated in the present study, and was primarily enriched in biological processes associated with the mitotic cell cycle, including cell cycle chromatid segregation, G1/S transition of mitotic cells and DNA replication. The *BUB* family of genes encode proteins that are involved in a large multi-protein kinetochore complex, and are hypothesized to be key components of the checkpoint regulatory pathway ([@b30-ol-0-0-4526]). *BUB1* encodes a serine/threonine-protein kinase that is critical in mitosis, and functions partly through the phosphorylation of members of the mitotic checkpoint complex and activation of the spindle checkpoint ([@b31-ol-0-0-4526]). *BUB1* accumulates at unattached kinetochores where it mediates the recruitment of mitotic arrest deficient (Mad) dimers ([@b32-ol-0-0-4526]). Combined with Mad, *BUB1* prevents the premature separation of sister chromatids until all the chromosomes are correctly attached to kinetochores, which leads to correct chromosome segregation ([@b33-ol-0-0-4526]). Therefore, *BUB1* may promote the growth of cancer cells in glioblastoma primarily by regulating the mitotic cell cycle. In addition, it appears that the mutation of mitotic spindle checkpoint genes is associated with the evolution of certain human cancers, particularly those with aneuploidy ([@b34-ol-0-0-4526]). Glioblastoma exhibits a high degree of aneuploidy ([@b35-ol-0-0-4526]) and the upregulation of *BUB1* in GASCs may increase the tumorigenesis of glioblastoma.

CDC20 appears to act as a regulatory protein interacting with several other proteins at multiple points in the cell cycle ([@b36-ol-0-0-4526]). In the present study, the *CDC20* gene was upregulated and enriched in cell cycle and oocyte meiosis pathways. *CDC20* is an activator protein that regulates the anaphase-promoting complex ubiquitin ligase, which is considered to be crucial in governing certain cellular processes ([@b37-ol-0-0-4526]), including the interaction with specific ubiquitin substrates for their subsequent degradation by the 26S proteasome at various points during cell cycle progression; this results in the forwards progression of the cell cycle in a unidirectional manner ([@b38-ol-0-0-4526]). Previous studies have demonstrated that *CDC20* is highly expressed in various types of human tumors, including breast ([@b39-ol-0-0-4526]) and cervical cancer ([@b40-ol-0-0-4526]), where it functions as an oncoprotein. Marucci *et al* ([@b41-ol-0-0-4526]) reported that, in glioblastoma, *CDC20* expression is upregulated, which is consistent with the present results. This implies that *CDC20* may promote glioblastoma occurrence by regulating cellular processes. In addition, Bie *et al* ([@b42-ol-0-0-4526]) observed that the expression levels of mitotic spindle assembly checkpoint gene *CDC20* is correlated with the grade of glioblastoma. The expression of *CDC20* is regulated by *BRCA1*, a susceptibility gene that greatly increases the risk of breast and other types of cancer ([@b43-ol-0-0-4526]), and is expressed differently depending on the age of the patient ([@b44-ol-0-0-4526]). In the present study, *BRCA1* and its target gene, *CDC20*, were upregulated. This leads to the hypothesis that *BRCA1* acts on glioblastoma, and is expressed at various levels in patients of various ages, regulating the expression of target genes that are associated with tumor grade or age of the patient, including *CDC20*. Therefore, *BRCA1* and its target genes are of significant value in clinical research, and *BRCA1* may be used as an anti-cancer drug target.

According to the present study, *PLK1* was upregulated and enriched in pathways associated with the cell cycle, oocyte meiosis and progesterone-mediated oocyte maturation. PLK1 is a serine/threonine kinase and is critical in centrosome maturation ([@b45-ol-0-0-4526]), mitotic entry ([@b46-ol-0-0-4526]), bipolar spindle formation ([@b47-ol-0-0-4526],[@b48-ol-0-0-4526]), metaphase-to-anaphase transition ([@b49-ol-0-0-4526]) and cytokinesis ([@b50-ol-0-0-4526]) in the mitotic phase of the cell cycle. Foong *et al* ([@b51-ol-0-0-4526]) demonstrated that increased expression of PLK1 is an independent, negative prognostic factor in glioma and is associated with proliferative and mesenchymal molecular subclasses, which characterize highly recurrent and aggressive tumors ([@b52-ol-0-0-4526]). PLK1 has become a primary target in brain tumor treatment, and its inhibition has been shown to result in 80--90% growth suppression in a panel of pediatric cancer cells, including glioblastoma, following 72 h of treatment ([@b52-ol-0-0-4526]). Therefore, in GASCs, *PLK1* upregulation may promote the cell cycle, leading to the growth of glioblastoma.

*CCNA2* belongs to a highly conserved cyclin family and is expressed in almost all tissues of the human body ([@b53-ol-0-0-4526]). The encoded protein is crucial in the control of the cell cycle at G1/S and G2/M transition points, and this is essential in embryonic cells and the hematopoietic lineage ([@b54-ol-0-0-4526]). Overexpression of *CCNA2* is involved in tumor transformation and progression in numerous types of cancer ([@b55-ol-0-0-4526]). Another member of the cyclin family, CCND2, is critical in cell cycle progression and tumorigenicity of glioblastoma stem cells ([@b56-ol-0-0-4526]). As expected, the present data revealed that *CCNA2* was upregulated, which is in accordance with the function of CCNA2 in cancer. According to the pathway enrichment results, *CCNA2* was enriched in cell cycle and progesterone-mediated oocyte maturation pathways, in which *CDK1*, *BUB1* and *PLK1* were also involved. The present results indicate that *CCNA2* promotes the growth of glioblastoma by participating in the cell cycle. However, few studies have reported the association between oocyte maturation and glioblastoma, revealing that this may be a novel insight in glioblastoma.

In conclusion, the present study identified several significant genes in glioblastoma, including *CDK1*, *BUB1*, *CDC20*, *CCNA2*, *PLK1* and *BRCA1*, which are all upregulated and may play various roles in the biological function of GASCs. These significant DEGs may promote the tumorigenesis of glioblastoma as they are involved in major biological pathways, including cell cycle, mitosis, p53 signaling and DNA replication. However, since the sample size used in this study is small and no experiments have been performed to confirm the conclusions, additional analyses of experimental studies are required to investigate the genes associated with glioblastoma.

![Heat map of gene expression in GB-associated stromal and control stromal cells. The rows indicate the expression levels of genes, and columns indicate different samples. Red, upregulated genes; green, downregulated genes. GB, glioblastoma.](ol-11-06-3999-g00){#f1-ol-0-0-4526}

![Protein-protein interaction network of differentially expressed genes in glioblastoma-associated stromal cells. Red nodes, upregulated genes; green nodes, downregulated genes.](ol-11-06-3999-g01){#f2-ol-0-0-4526}

![Sub-network constructed from the protein-protein interaction network. Red nodes, upregulated genes.](ol-11-06-3999-g02){#f3-ol-0-0-4526}

###### 

Enriched GO categories and KEGG pathway enrichment analysis of DEGs in glioblastoma-associated stromal cells.

  A, KEGG analysis of upregulated DEGs.                                                                                      
  ----------------------------------------- ------------ ----------------------------------------------------------- ------- --------------
  KEGG                                      4110         Cell cycle                                                  124     0
  KEGG                                      3030         DNA replication                                               36    3.47×10^−13^
  KEGG                                      4114         Oocyte meiosis                                              112     5.49×10^−10^
  KEGG                                      4914         Progesterone-mediated oocyte maturation                       86    2.10×10^−7^
  KEGG                                      4115         p53 signaling pathway                                         68    2.13×10^−6^
  KEGG                                      3430         Mismatch repair                                               23    5.90×10^−4^
  KEGG                                        240        Pyrimidine metabolism                                         99    1.57×10^−3^
  KEGG                                      3410         Base excision repair                                          33    2.39×10^−3^
  KEGG                                      3420         Nucleotide excision repair                                    44    6.85×10^−3^
  KEGG                                      3440         Homologous recombination                                      28    1.22×10^−2^
                                                                                                                             
  B, KEGG analysis of downregulated DEGs.                                                                                    
                                                                                                                             
  Category                                  Term         Biological process                                          Count   P-value
                                                                                                                             
  KEGG                                      4920         Adipocytokine signaling pathway                               68    3.85×10^−3^
  KEGG                                      4960         Aldosterone-regulated sodium reabsorption                     42    7.26×10^−3^
  KEGG                                      4621         NOD-like receptor signaling pathway                           58    1.75×10^−2^
  KEGG                                      4964         Proximal tubule bicarbonate reclamation                       23    1.99×10^−2^
  KEGG                                        640        Propanoate metabolism                                         32    3.69×10^−2^
  KEGG                                      4060         Cytokine-cytokine receptor interaction                      265     3.93×10^−2^
                                                                                                                             
  C, GO analysis of upregulated DEGs.                                                                                        
                                                                                                                             
  Category                                  Term         Biological process                                          Count   P-value
                                                                                                                             
  BP                                        GO:0000070   Mitotic sister chromatid segregation                          53    0
  BP                                        GO:0000075   Cell cycle checkpoint                                       226     0
  BP                                        GO:0000226   Microtubule cytoskeleton organization                       297     0
  BP                                        GO:0000278   Mitotic cell cycle                                          816     0
  BP                                        GO:0000280   Nuclear division                                            346     0
  BP                                        GO:0000819   Sister chromatid segregation                                  56    0
  BP                                        GO:0006259   DNA metabolic process                                       896     0
  BP                                        GO:0006260   DNA replication                                             277     0
  BP                                        GO:0006261   DNA-dependent DNA replication                               100     0
  BP                                        GO:0006270   DNA replication initiation                                    29    0
                                                                                                                             
  D, GO analysis of downregulated DEGs.                                                                                      
                                                                                                                             
  Category                                  Term         Biological process                                          Count   P-value
                                                                                                                             
  BP                                        GO:0008217   Reg. of blood pressure                                        147   9.85×10^−6^
  BP                                        GO:0045776   Negative regulation of blood pressure                         35    3.08×10^−4^
  BP                                        GO:0071260   Cellular response to mechanical stimulus                      57    1.98×10^−3^
  BP                                        GO:0035094   Response to nicotine                                          31    2.98×10^−3^
  BP                                        GO:0016486   Peptide hormone processing                                    32    3.27×10^−3^
  BP                                        GO:0002864   Reg. of acute inflammatory response to antigenic stimulus     10    3.73×10^−3^
  BP                                        GO:0031272   Reg. of pseudopodium assembly                                 10    3.73×10^−3^
  BP                                        GO:0016485   Protein processing                                            160   3.95×10^−3^
  BP                                        GO:0051239   Reg. of multicellular organismal processes                  1963    4.20×10^−3^
  BP                                        GO:0006952   Defense response                                            1372    4.25×10^−3^

GO, gene ontology; DEG, differentially expressed gene; BP, biological process; KEGG, Kyoto Encyclopedia of Genes and Genomes; Reg., regulation.

###### 

Functional annotation of differentially expressed genes in glioblastoma-associated stromal cells.

  Category                 n     Gene
  ------------------------ ----- -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Upregulated                    
    TF                     11    BRCA1, BRIP1, CDK2, HEYL, HMGB2, IRX5, MEF2C, MEIS2, MYBL2, RBL1, TBX2
    TAG oncogene             9   CCNA2, CCND2, CEP55, DUSP26, FGF5, HGF, MYBL2, NET1, PTTG1
    TAG tumor suppressor   23    AKAP12, BARD1, BLM, BMP2, BRCA1, BUB1B, CDH13, CHEK1, DAB2IP, E2F1, FANCD2, ID4, ITGB3, LIMD1, LIN9, MFSD2A, PCDH10, PTPN3, RBL1, STARD13, TFPI2, TMEFF2, ZFHX3
  Downregulated                  
    TF                       6   ARNT2, DDIT3, HES2, MITF, NFIA, NR3C2
    TAG oncogene             3   ARHGEF5, DDIT3, MRAS
    TAG tumor suppressor   10    ATP8A2, BHLHE41, CABLES1, CDH4, DAB2, HRASLS2, LGI1, PLA2G16, RARRES3, RPS6KA2

TF, transcription factor; TAG, tumor-associated genes. BRCA1, breast cancer 1, early onset; BRIP1, BRCA1 interacting protein C-terminal helicase 1; CDK2, cyclin-dependent kinase 2; HEYL, hes-related family bHLH transcription factor with YRPW motif-like; HMGB2, high mobility group box 2; IRX5, iroquois homeobox 5; MEF2C, myocyte enhancer factor 2C; MEIS2, Meis homeobox 2; MYBL2, v-myb avian myeloblastosis viral oncogene homolog-like 2; RBL1, retinoblastoma-like 1; TBX2, T-box 2; CCNA2, cyclin A2; CCND2, cyclin D2; CEP55, centrosomal protein 55kDa; DUSP26, dual specificity phosphatase 26 (putative); FGF5, fibroblast growth factor 5; HGF, hepatocyte growth factor; NET1, neuroepithelial cell transforming 1; PTTG1, pituitary tumor-transforming 1; AKAP12, a kinase anchor protein; BARD1, BRCA1 associated RING domain 1; BLM, Bloom syndrome RecQ like helicase; BMP2, bone morphogenetic protein 2; BUB1B, BUB1 mitotic checkpoint serine/threonine kinase B; CDH13, cadherin 13; CHEK1, checkpoint kinase 1; DAB2IP, DAB2 interacting protein; E2F1, E2F transcription factor 1; FANCD2, Fanconi anemia complementation group D2; ID4, inhibitor of DNA binding 4, dominant negative helix-loop-helix protein; ITGB3, integrin subunit beta 3; LIMD1, LIM domains containing 1; LIN9, lin-9 DREAM MuvB core complex component; MFSD2A, major facilitator superfamily domain containing 2A; PCDH10, protocadherin 10; PTPN3, protein tyrosine phosphatase, non-receptor type 3; STARD13, StAR related lipid transfer domain containing 13; TFPI2, tissue factor pathway inhibitor 2; TMEFF2, transmembrane protein with EGF like and two follistatin like domains 2; ZFHX3, zinc finger homeobox 3; ARNT2, ary-hydrocarbon receptor nuclear translocator 2; DDIT3, DNA damage inducible transcript 3; HES2, hairy and enhancer of split 2; MITF, microphthalmia-associated transcription factor; NFIA, nuclear factor I/A; NR3C2, nuclear receptor subfamily 3 group C member 2; ARHGEF5, Rho guanine nucleotide exchange factor 5; MRAS, muscle RAS oncogene homolog; ATP8A2, ATPase, aminophospholipid transporter, class I, type 8A, member 2; BHLHE41, basic helix-loop-helix family member e41; CABLES1, Cdk5 and Abl enzyme substrate 1; CDH4, cadherin 4, type 1, R-cadherin; DAB2, Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila); HRASLS2, HRAS like suppressor 2; LGI1, leucine-rich, glioma inactivated 1; PLA2G16, phospholipase A2 group XVI; RARRES3, retinoic acid receptor responder (tazarotene induced) 3; RPS6KA2, ribosomal protein S6 kinase, 90kDa, polypeptide 2.

###### 

GO terms and KEGG pathways of DEGs in the sub-network.

  A, Enriched pathways of DEGs in sub-network                                                                  
  --------------------------------------------- ------------ ----------------------------------------- ------- --------------
  KEGG                                          3030         DNA replication                           12      0
  KEGG                                          4110         Cell cycle                                29      0
  KEGG                                          4114         Oocyte meiosis                            15      1.55×10^−14^
  KEGG                                          4914         Progesterone-mediated oocyte maturation   11      1.29×10^−10^
  KEGG                                          4115         p53 signaling pathway                       9     5.41×10^−9^
  KEGG                                            240        Pyrimidine metabolism                       7     2.25×10^−5^
  KEGG                                          3430         Mismatch repair                             4     4.28×10^−5^
  KEGG                                          3420         Nucleotide excision repair                  4     5.72×10^−4^
  KEGG                                          3440         Homologous recombination                    3     1.84×10^−3^
  KEGG                                          3410         Base excision repair                        3     2.97×10^−3^
                                                                                                               
  B, Enriched GO terms of DEGs in sub-network                                                                  
                                                                                                               
  Category                                      Term         Biological Process                        Count   P-value
  BP                                            GO:0000070   Mitotic sister chromatid segregation        20    0
  BP                                            GO:0000075   Cell cycle checkpoint                       27    0
  BP                                            GO:0000082   G1/S transition of mitotic cell cycle       24    0
  BP                                            GO:0000226   Microtubule cytoskeleton organization       36    0
  BP                                            GO:0000278   Mitotic cell cycle                        101     0
  BP                                            GO:0000280   Nuclear division                            62    0
  BP                                            GO:0000819   Sister chromatid segregation                21    0
  BP                                            GO:0006259   DNA metabolic process                       72    0
  BP                                            GO:0006260   DNA replication                             39    0
  BP                                            GO:0006261   DNA-dependent DNA replication               22    0

GO, gene ontology; DEG, differentially expressed gene; BP, biological process; KEGG, Kyoto Encyclopedia of Genes and Genomes.
